Targeted Drug Therapy for Intracranial Tumors

WANG Han, WANG Yue-long, LIU Zhi-yong, XU Jian-guo

Abstract

Intracranial tumors seriously affect the physical and mental health of humans. Due to variations in the nature and the growth site of tumors, individualized and specific treatment of patients with intracranial tumor has become a hotspot topic of research, and targeted drug therapy of intracranial tumors, an important subspecialty of precision medicine, has become a key issue that scientists are working hard to tackle. At present, the rapid development in molecular biology and genomics has provided corresponding targets for precision therapies of tumors. However, the blood-brain barrier and blood-tumor barrier prevent drugs from reaching intracranial targets. Therefore, finding effective ways to elevate the concentration of intracranial drugs has become the key issue concerning existing targeted therapies for intracranial tumors. Herein, we reviewed the current status of targeted drug therapy for different intracranial tumors and discussed their efficacy, intending to provide new perspectives for the treatment of intracranial tumors with targeted drugs in the future.

 

Keywords: Glioma, Meningioma, Pituitary adenoma, Schwannoma, Craniopharyngioma, Targeted drug therapy

 

Full Text:

PDF


References


HOWLADER N. SEER Cancer Statistics Review， 1975–2009 (Vintage 2009 Populations) based on November 2011 SEER data submission， posted to the SEER web site， 2012. (2012-08-20) [2021-10-01]. https://seer.cancer.gov/archive/csr/1975-2009-pops09/results-figure/sect-01-intro1-6pgs.pdf.

OSTROM Q T， NIRAV P， GINO C， et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol，2020，22(12 Suppl 2): iv1–iv96.

BREM S S， BIERMAN P J， BLACK P， et al. Central nervous system cancers: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw，2005，3(5): 644–690.

PUCHNER M J， HERMANN H D， BERGER J， et al. Surgery, tamoxifen, carboplatin, and radiotherapy in the treatment of newly diagnosed glioblastoma patients. J Neurooncol，2000，49(2): 147–155.

STUPP R， MASON W P， VANDEN B M J， et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med， 2005，352(10): 987–996.

PARSONS D W， JONES S， ZHANG X， et al. An integrated genomic analysis of human glioblastoma multiforme. Science，2008，321(5897): 1807–1812.

CARRASCO G E， SACEDA M， MARTINEZ L I. Role of receptor tyrosine kinases and their ligands in glioblastoma. Cells，2014，3(2): 199–235.

HEIMBERGER A B， HLATKY R， SUKI D， et al. Prognostic effect of epidermal growth factor receptor and EGFRvⅢ in glioblastoma multiforme patients. Clin Cancer Res，2005，11(4): 1462–1466.

SIEGELIN M D， BORCZUK A C. Epidermal growth factor receptor mutations in lung adenocarcinoma. Lab Invest，2014，94(2): 129–137.

HAMER P. Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro Oncol，2010，12(3): 304–316.

RICH J N， REARDON DA， PEERY T， et al. Phase Ⅱ trial of gefitinib in recurrent glioblastoma. J Clin Oncol，2004，22(1): 133–142.

FOULADI M， STEWART C F， BLANEY S M， et al. A molecular biology and phase Ⅱ trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Neurooncol， 2013，114(2): 173–179.

GILBERT M R， DIGNAM J J， ARMSTRONG T S， et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med， 2014，370(8): 699–708.

CHINOT O L， WICK W， MASON W， et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med，2014，370(8): 709–722.

BRENNAN C W， VERHAAK R G， MCKENNA A， et al. The somatic genomic landscape of glioblastoma. Cell，2013，155(2): 462–477.

CHINNAIYAN P， WON M， WEN P Y， et al. RTOG 0913: A phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys，2013，86(5): 880–884.

MA D J， GALANIS E， ANDERSON S K， et al. A phase Ⅱ trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro Oncol，2015，17(9): 1261–1269.

LASSEN U， SORENSEN M， GAZIELl T B， et al. Phase Ⅱ study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme. Anticancer Res，2013，33(4): 1657–1660.

PARK J W， BARRETTE A M， WANG W， et al. Mapk pathway inhibition sensitizes to immunotherapy in braf-mutant gliomas. Neuro Oncol，2021，23(Suppl 1): i3–i4.

ROCHET N M， DRONCA R S， KOTTSCHADE L A， et al. Melanoma brain metastases and vemurafenib: Need for further investigation. Mayo Clin Proc，2012，87(10): 976–981.

GARRY C， JAN-MICHAEL W， VERONIKA D， et al. Dabrafenib treatment in a patient with an epithelioid glioblastoma and BRAF V600E mutation. Int J Mol Sci，2018，19(4): 1090.

FLAHERTY K T， INFANTE J R， DAUD A， et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med， 2012，367(18): 1694–1703.

NAZARIAN R， SHI H， WANG Q， et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature， 2010，468(7326): 973–977.

HYMAN D M， PUZANOV I， SUBBIAH V， et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med，2015，373(8): 726–736.

LOUVEAU A， SMIRNOV I， KEYES T J， et al. Structural and functional features of central nervous system lymphatic vessels. Nature，2015， 523(7560): 337–341.

PREUSSER M， LIM M， HAFLER D A， et al. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol， 2015，11(9): 504–514.

ZHU G， ZHANG Q， ZHANG J， et al. Targeting tumor-associated antigen: A promising CAR-T therapeutic strategy for glioblastoma treatment. Front Pharmacol， 2021， 12: 661606[2021-10-01]. https://doi. org/10.3389/fphar.2021.661606.

KUPPNER M C， HAMOU M F， BODMER S， et al. The glioblastoma-derived T-cell suppressor factor/transforming growth factor beta 2 inhibits the generation of lymphokine-activated killer (LAK) cells. Int J Cancer，1988，42(4): 562–567.

BRANDES A A， CARPENTIER A F， KESARI S， et al. A Phase Ⅱ randomized study of galunisertib monotherapy or galunisertib plus omustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro Oncol，2016，18(8): 1146–1156.


Refbacks

  • There are currently no refbacks.